Trial Profile
Phase 2 Study of ADXS11-001 in Subjects With Persistent/Recurrent, Loco-Regional or Metastatic Squamous Cell Carcinoma of the Anorectal Canal
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Mar 2023
Price :
$35
*
At a glance
- Drugs Axalimogene filolisbac (Primary)
- Indications Anal cancer; Rectal cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms FAWCETT
- Sponsors Advaxis
- 22 Mar 2023 This study protocol has been amended as primary endpoint (Number of subjects with adverse events) has been removed and trial focus has been shifted to TU only from TU and AR.
- 11 Mar 2020 Status changed from active, no longer recruiting to completed.
- 04 Mar 2019 Planned End Date changed from 1 Mar 2022 to 1 May 2019.